Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Infectious Diseases

• Publication date

  2014-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/infdis/jiu095PMID 24532601PMCID PMC4110457
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antimicrobial efflux pumps and Mycobacterium tuberculosis drug tolerance: evolutionary considerations.

  2013cited by this paper
• Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.

  2013cited by this paper
• Efflux Inhibition with Verapamil Potentiates Bedaquiline in Mycobacterium tuberculosis

  2013cited by this paper
• Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium tuberculosis

  2012cited by this paper
• Efflux-Mediated Drug Resistance in Bacteria

  2012cited by this paper
• Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

  2011cited by this paper
• Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism.

  2011influential reference
• Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates

  2011cited by this paper
• Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis.

  2010cited by this paper
• Rv1218c, an ABC Transporter of Mycobacterium tuberculosis with Implications in Drug Discovery

  2010cited by this paper
• Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!

  2010cited by this paper
• Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells.

  2010cited by this paper
• A Mycobacterium tuberculosis Sigma Factor Network Responds to Cell-Envelope Damage by the Promising Anti-Mycobacterial Thioridazine

  2010cited by this paper
• Faculty Opinions recommendation of Verapamil for cluster headache. Clinical pharmacology and possible mode of action.

  2009cited by this paper
• Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion.

  2009cited by this paper
• The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

  2009cited by this paper
• Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

  2009cited by this paper
• Verapamil for Cluster Headache. Clinical Pharmacology and Possible Mode of Action

  2009cited by this paper
• Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

  2009cited by this paper
• Efflux-Mediated Drug Resistance in Bacteria

  2009cited by this paper
• The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

  2009cited by this paper
• A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance

  2009cited by this paper
• Identification of Mutations Related to Streptomycin Resistance in Clinical Isolates of Mycobacterium tuberculosis and Possible Involvement of Efflux Mechanism

  2008cited by this paper
• Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis*

  2008cited by this paper
• Inhibitors of Ca2+ and K+ transport enhance intracellular killing of M. tuberculosis by non-killing macrophages.

  2008cited by this paper
• Why Is Long-Term Therapy Required to Cure Tuberculosis?

  2007cited by this paper
• Black Pepper and its Pungent Principle-Piperine: A Review of Diverse Physiological Effects

  2007cited by this paper
• Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study

  2006cited by this paper
• Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.

  2006cited by this paper
• Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages.

  2005cited by this paper
• A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis

  2005cited by this paper
• Mycobacterium tuberculosis Isolate with a Distinct Genomic Identity Overexpresses a Tap-Like Efflux Pump

  2004cited by this paper
• M. tuberculosis persistence, latency, and drug tolerance.

  2004cited by this paper
• Clinical Concentrations of Thioridazine Kill Intracellular Multidrug-Resistant Mycobacterium tuberculosis

  2003cited by this paper
• Comparison of the pharmacokinetics of verapamil in the pregnant and non-pregnant rabbit: study of maternal and foetal tissue levels

  2000cited by this paper
• Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration.

  2000cited by this paper
• A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

  2000cited by this paper
• Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.

  1998cited by this paper
• Reversal of multidrug resistance by verapamil analogues.

  1995cited by this paper
• Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis

  1995cited by this paper
• Low-dose calcium pretreatment to prevent verapamil-induced hypotension.

  1992cited by this paper
• J774 macrophages secrete antibiotics via organic anion transporters.

  1992cited by this paper
• Near-total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates.

  1988cited by this paper
• Steady state verapamil tissue distribution in the dog: differing tissue accumulation.

  1986cited by this paper
• Influence of piperine on rifampicin blood levels in patients of pulmonary tuberculosis.

  1985cited by this paper
• Comparative cardiovascular actions of verapamil and its major metabolites in the anaesthetised dog.

  1978cited by this paper
• Inhibition of Dihydrostreptomycin Binding to Mycobacterium smegmatis by Monovalent and Divalent Cation Salts

  1975cited by this paper
• Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.

  1972cited by this paper
• Activation of pyrazinamide and nicotinamide in acidic environments in vitro.

  1954cited by this paper

• The power of resistance: mechanisms of antimicrobial resistance in Mycobacterium tuberculosis and its impact on tuberculosis management

  2026cites this paper
• Inhibitory Effect of Verapamil in the Treatment of Mixed Biofilm of Candida albicans and Staphylococcus aureus

  2026cites this paper
• Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity

  2025cites this paper
• Verapamil Suppresses the Development of Resistance Against Anti-Tuberculosis Drugs in Mycobacteria

  2025cites this paper
• Identification of mycobacterial efflux pump inhibiting compounds from Berberis holstii Engl. and determination of their mechanism of action

  2025cites this paper
• Combating Multi-drug Resistant Mycobacterium Species by Efflux Pump Inhibitors: Contemporary Trends

  2025cites this paper
• Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning

  2024cites this paper
• Metabolic Rewiring of Mycobacterium tuberculosis upon Drug Treatment and Antibiotics Resistance

  2024cites this paper
• Targeting mycobacterial efflux system to enhance tuberculosis therapy

  2024cites this paper
• Boosting Gentamicin Activity Against Pseudomonas aeruginosa Using Nano-formulation of Curcumin

  2024cites this paper
• Investigation of the role of Cremophor RH 40 and Cremophor EL in the inhibition of efflux pump of Pseudomonas aeruginosa

  2024cites this paper
• Three-Dimensional Culture Modelling Reveals Divergent Mycobacterium tuberculosis Virulence and Antimicrobial Treatment Response

  2024cites this paper
• Role of Berberine as a Potential Efflux Pump Inhibitor against MdfA from Escherichia coli: In Vitro and In Silico Studies

  2023cites this paper
• A Dose‐Finding Study to Guide Use of Verapamil as an Adjunctive Therapy in Tuberculosis

  2023cites this paper
• A dose-finding study to guide use of verapamil as an adjunctive therapy in tuberculosis

  2023cites this paper
• Traditional Medicine Combination Therapy Is A Promising Strategy for MRSA Infection

  2023cites this paper
• Gated Calcium Ion Channel and Mutation Mechanisms in Multidrug-Resistant Tuberculosis

  2023cites this paper
• C-1 Substituted isoquinolines potentiate the antimycobacterial activity of rifampicin and ethambutol

  2023cites this paper
• Redefining tuberculosis: an interview with Lalita Ramakrishnan

  2023cites this paper
• Clinical Resistant Strains of Enterococci and Their Correlation to Reduced Susceptibility to Biocides: Phenotypic and Genotypic Analysis of Macrolides, Lincosamides, and Streptogramins

  2023cites this paper
• The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance

  2023influential citation
• Discovering interrelated natural mutations of efflux pump KmrA from Klebsiella pneumoniae that confer increased multidrug resistance

  2022cites this paper
• SAR investigation and optimization of benzimidazole-based derivatives as antimicrobial agents against Gram-negative bacteria.

  2022cites this paper
• Gaucher disease protects against tuberculosis

  2022cites this paper
• Unraveling the mechanisms of intrinsic drug resistance in Mycobacterium tuberculosis

  2022cites this paper
• The evolving biology of Mycobacterium tuberculosis drug resistance

  2022cites this paper
• Verapamil regulates the macrophage immunity to Mycobacterium tuberculosis through NF-κB signaling.

  2022cites this paper
• Uncoupler SYP-14288 inducing multidrug resistance of Phytophthora capsici through overexpression of cytochrome P450 monooxygenases and P-glycoprotein.

  2022cites this paper
• Targeting Host and Bacterial Signaling Pathways in Tuberculosis: An Effective Strategy for the Development of Novel Anti-tubercular Therapies

  2021cites this paper
• Nifedipine Potentiates Susceptibility of Salmonella Typhimurium to Different Classes of Antibiotics

  2021cites this paper
• Critical discussion on drug efflux in Mycobacterium tuberculosis

  2021influential citation
• Targeting the Mycobacterium tuberculosis Stringent Response as a Strategy for Shortening Tuberculosis Treatment

  2021cites this paper
• The Mycobacterial Efflux Pump EfpA Can Induce High Drug Tolerance to Many Antituberculosis Drugs, Including Moxifloxacin, in Mycobacterium smegmatis

  2021cites this paper
• Coexpression of MmpS5 and MmpL5 Contributes to Both Efflux Transporter MmpL5 Trimerization and Drug Resistance in Mycobacterium tuberculosis

  2021cites this paper
• Prospects and Obstacles for Clinical Use of the Inhibitors of Mycobacterium tuberculosis Efflux Pumps

  2021cites this paper
• KatG as Counterselection Marker for Nontuberculous Mycobacteria

  2020cites this paper
• Targeting bedaquiline mycobacterial efflux pump to potentially enhance therapy in Mycobacterium abscessus

  2020cites this paper
• Repurposed drug candidates for antituberculosis therapy.

  2020cites this paper
• The within-host evolution of antimicrobial resistance in Mycobacterium tuberculosis

  2020cites this paper
• Are antibacterial effects of non-antibiotic drugs random or purposeful because of a common evolutionary origin of bacterial and mammalian targets?

  2020cites this paper
• A framework to activate the health and safety regulations in the Egyptian construction industry

  2020cites this paper
• The impact of hypertension and use of calcium channel blockers on tuberculosis treatment outcomes

  2020cites this paper
• Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs

  2020cites this paper
• Oxidative Phosphorylation—an Update on a New, Essential Target Space for Drug Discovery in Mycobacterium tuberculosis

  2020cites this paper
• STRATEGIES TO COMBAT DRUG-RESISTANT TUBERCULOSIS: INHALABLE MICROPARTICLES FORMULATED WITH ANTI-TUBERCULAR ANTIBIOTICS AND EFFLUX PUMP INHIBITORS

  2019cites this paper
• The treatment of melioidosis: is there a role for repurposed drugs? A proposal and review

  2019cites this paper
• Modulatory effects of verapamil in rifampicin activity against Mycobacterium tuberculosis.

  2019cites this paper
• Diverse Clinical Isolates of Mycobacterium tuberculosis Develop Macrophage-Induced Rifampin Tolerance

  2019cites this paper
• Specific N‐demethylation of verapamil by cytochrome P450 from Streptomyces griseus ATCC 13273

  2019cites this paper
• Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections

  2019cites this paper
• Chemical disarming of isoniazid resistance in Mycobacterium tuberculosis

  2019cites this paper
• Verapamil Improves the Activity of Bedaquiline against Mycobacterium abscessus In Vitro and in Macrophages

  2019cites this paper
• Subcellular antibiotic visualization reveals a dynamic drug reservoir in infected macrophages

  2019cites this paper
• Antituberculosis agents: Beyond medicinal chemistry rules

  2019cites this paper
• Verapamil as an Efflux Inhibitor Against Drug Resistant Mycobacterium Tuberculosis: A Review

  2019cites this paper
• TNF Induces Pathogenic Programmed Macrophage Necrosis in Tuberculosis through a Mitochondrial-Lysosomal-Endoplasmic Reticulum Circuit

  2019cites this paper
• Transport mechanism of Mycobacterium tuberculosis MmpL/S family proteins and implications in pharmaceutical targeting

  2019cites this paper
• Strategies to Overcome Antimicrobial Resistance (AMR) Making Use of Non-Essential Target Inhibitors: A Review

  2019cites this paper
• Drug Susceptibility of Individual Mycobacterial Cells

  2019cites this paper
• Intramacrophage Mycobacterium tuberculosis efflux pump gene regulation after rifampicin and verapamil exposure

  2018cites this paper
• The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box.

  2018cites this paper
• Efflux Activity Differentially Modulates the Levels of Isoniazid and Rifampicin Resistance among Multidrug Resistant and Monoresistant Mycobacterium tuberculosis Strains

  2018cites this paper
• Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis

  2018cites this paper
• Multifaceted remodeling by vitamin C boosts sensitivity of Mycobacterium tuberculosis subpopulations to combination treatment by anti-tubercular drugs

  2018cites this paper
• Macrophage-induced rifampin tolerance across Mycobacterium tuberculosis lineages is Rv1258c-dependent

  2018cites this paper
• The zebrafish model of tuberculosis - no lungs needed

  2018influential citation
• Identification of protective postexposure mycobacterial vaccine antigens using an immunosuppression-based reactivation model in the zebrafish

  2018cites this paper
• Molecular modelling and simulation studies of the Mycobacterium tuberculosis multidrug efflux pump protein Rv1258c

  2018cites this paper
• A Protein Complex from Human Milk Enhances the Activity of Antibiotics and Drugs against Mycobacterium tuberculosis

  2018cites this paper
• Adjunctive use of celecoxib with anti-tuberculosis drugs: evaluation in a whole-blood bactericidal activity model

  2018cites this paper
• Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model

  2018cites this paper
• Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis

  2018cites this paper
• Drug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development

  2018cites this paper
• Recent advances for identification of new scaffolds and drug targets for Mycobacterium tuberculosis

  2018cites this paper
• University of Groningen Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model Pieterman,

  2018cites this paper
• Calcium Ion Channels: Roles in Infection and Sepsis Mechanisms of Calcium Channel Blocker Benefits in Immunocompromised Patients at Risk for Infection

  2018cites this paper
• Animal models of tuberculosis: Lesson learnt

  2018cites this paper
• DNA Replication in Mycobacterium tuberculosis

  2017cites this paper
• Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosis

  2017cites this paper
• Implications of Chromosomal Mutations for Mycobacterial Drug Resistance

  2017cites this paper
• Targeting Energy Metabolism in Mycobacterium tuberculosis, a New Paradigm in Antimycobacterial Drug Discovery

  2017cites this paper
• Reversed isoniazids: Design, synthesis and evaluation against Mycobacterium tuberculosis.

  2017cites this paper
• In silico and in vitro screening of FDA-approved drugs for potential repurposing against tuberculosis

  2017cites this paper
• Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis

  2017cites this paper
• Activity of moxifloxacin and linezolid against Mycobacterium tuberculosis in combination with potentiator drugs verapamil, timcodar, colistin and SQ109.

  2017cites this paper
• Antimicrobial Activity and Resistance: Influencing Factors

  2017cites this paper
• Verapamil Increases the Bioavailability and Efficacy of Bedaquiline but Not Clofazimine in a Murine Model of Tuberculosis

  2017cites this paper
• Identification of novel antigen candidates for a tuberculosis vaccine in the adult zebrafish (Danio rerio)

  2017cites this paper
• Inhaled Drug Combinations

  2016cites this paper
• Efflux Pumps in Mycobacteria: Antimicrobial Resistance, Physiological Functions, and Role in Pathogenicity

  2016cites this paper
• Antimicrobial Drug Efflux Systems as Components of Bacterial Stress Responses

  2016cites this paper
• Synthesis, characterization and biological activity of fluorescently labeled bedaquiline analogues

  2016cites this paper
• Genetic determinants and evolution of drug resistance in Mycobacterium tuberculosis in Vietnam : toward new diagnostic tools

  2016cites this paper
• Stringent Response Factors PPX1 and PPK2 Play an Important Role in Mycobacterium tuberculosis Metabolism, Biofilm Formation, and Sensitivity to Isoniazid In Vivo

  2016cites this paper
• Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.

  2016cites this paper
• Morphological changes and differentially expressed efflux pump genes in Mycobacterium tuberculosis exposed to a rifampicin and verapamil combination.

  2016cites this paper
• In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Tuberculosis Therapy.

  2016cites this paper
• Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis.

  2016cites this paper
• Improving Treatment of Mycobacterial Infections

  2016cites this paper
• Hybrid Triazoles: Design and Synthesis as Potential Dual Inhibitor of Growth and Efflux Inhibition in Methicillin Resistant Staphylococcus aureus

  2016cites this paper